GSK Kicks Off M&A Push As Deal Speculation And Sunny Skies Set The Scene For J.P. Morgan

 
• By Jessica Merrill

GSK will pay up to $1.15bn for IDRx, Lilly is said to be making a play for Scorpion, Biogen offered to buy Sage and Gilead announced a partnership with Leo Pharma ahead of the J.P. Morgan Healthcare Conference.

Rumored deals and some confirmed transactions garnered attention in the lead-up to J.P. Morgan (Shutterstock)

More from J.P. Morgan

More from R&D